Shares of Editas Medicine Inc. (NASDAQ:EDIT) rose 4.7% during mid-day trading on Friday . The company traded as high as $18.79 and last traded at $18.60, with a volume of 261,111 shares. The stock had previously closed at $17.76.

EDIT has been the subject of a number of recent analyst reports. Vetr upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 price target for the company in a report on Monday, May 9th. Cowen and Company restated a “buy” rating on shares of Editas Medicine in a report on Monday, May 16th. Zacks Investment Research downgraded shares of Editas Medicine from a “hold” rating to a “sell” rating in a report on Wednesday, May 18th. Finally, Jefferies Group initiated coverage on shares of Editas Medicine in a report on Thursday, June 2nd. They set a “hold” rating and a $35.00 price target for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Editas Medicine presently has an average rating of “Hold” and an average price target of $33.50.

The firm’s 50 day moving average is $24.33 and its 200-day moving average is $29.34. The company’s market capitalization is $652.85 million.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.54) EPS for the quarter, hitting analysts’ consensus estimates of ($0.54). Analysts expect that Editas Medicine Inc. will post ($2.59) earnings per share for the current fiscal year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.